Endocrine Therapy
Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery, according to results of a prospective study.
FDA expands Enhertu approval for breast cancer
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.
Adding anthracyclines to taxane-based chemotherapy beneficial in high-risk breast cancer
SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at San Antonio Breast Cancer Symposium.
FDA approves Datroway for advanced breast cancer
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.
Imlunestrant alone, with abemaciclib delays progression of advanced breast cancer
SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.
Strategies needed to reduce death due to low-risk breast cancer
Most breast cancer-specific deaths occur among patients diagnosed with stage I or II disease rather than more advanced disease, according to a SEER database analysis.
Inavolisib regimen extends PFS in PIK3CA-mutated advanced breast cancer
The addition of inavolisib to palbociclib and fulvestrant more than doubled PFS for certain patients with advanced breast cancer, according to results of a randomized phase 3 trial.
Breastfeeding after breast cancer is safe
Women who breastfeed after undergoing treatment for breast cancer are not at elevated risk for recurrence or new breast cancers, two studies presented at ESMO Congress showed.
Top in women’s health: Breast cancer risk tied to contraceptive device; miscarriage care
Women using the intrauterine system had an increased risk for breast cancer vs. women who were hormonal contraceptive nonusers, according to a research letter published in JAMA.
FDA accepts new drug application for nonhormonal hot flash drug elinzanetant
The FDA accepted a new drug application for elinzanetant, a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause, according to an industry press release.